SILAC proteomics analysis to discover effect sensors of EGFR inhibition

ABSTRACT: Targeted therapies against EGFR show clinical benefit, but resistance to these agents invariably develops. Thus, there is a need for dynamic biomarkers - effect sensors - that reflect treatment with EGFR therapeutics during therapy. Making use of SILAC-labeling we aimed to discover plasma membrane proteins that become differentially expressed after treatment with EGFR inhibitor erlotinib in three erlotinib-sensitive breast cancer cell lines.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Breast Cancer

SUBMITTER: Rolf de Boer  

LAB HEAD: Marcel A.T.M. van Vugt

PROVIDER: PXD005985 | Pride | 2018-10-18

REPOSITORIES: Pride